Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amarantus BioSciences Announces Close of $10M Equity Funding Facility With Centurion Private Equity, LLC
AMBS can Draw on this still for 22 months.. + the Monies from Brewer Sports Int & the Additional 1.4M recently announced.
No one just hands over this kind of Money if you are not Legit... LET BE REAL HERE.
http://www.marketwire.com/press-release/amarantus-biosciences-announces-close-10m-equity-funding-facility-with-centurion-private-otcbb-ambs-1572738.htm
The Statistical Significance is enough for AMBS to continue advancing MANF into IND-enabling and human clinical studies.
I go by what the CEO says, he has delivered so far, no reason to doubt him now.. You need to be patient, 1$ PPS will come but not as fast as you may want it.
Gerald addressed your concern , read the post of an addressed Email to a Stockholder
I stated in my last Chairman's Blog post that we were moving forward with IND-enabling and human clinical studies
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84094560
Fast Track, Accelerated Approval and Priority Review
Accelerating Availability of New Drugs for Patients with Serious Diseases
You time frame is way off especially with the Orphan Drug Status they AMBS are also pursuing read this....
http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm#fast
not a problem, all drugs take millions to get to market.
MANF + AMBS are dedicated to complete the task..
that summary you provided is for ischemia, which is not the main focus for MANF... Parkinson's Disease is and the Positive efficacy Data recently presented allows AMBS to continue advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies
the Time frame is a lot sooner than you are thinking.. just be patient.
no you are incorrect, the data was so positive and impressive that they are pushing forward with the following:
IND-enabling and human clinical studies
go re-read this post
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84094560
Desperation is Setting in Because: AMBS
IS advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies.
this equals swift rise in PPS and long term shareholder Value
http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html
Don't let anyone stand in your way of success
Holding all my Initial shares of AMBS and have Added every chance I have had. When someone wants you out of this its for a reason.
My reason to stay in is more important than theirs.
I trust me & the DD
they will IMO.. And I truly believe it will be AMGEN. I can't see them sit idly by as another Pharma Competitor gets the Premium version of the Drug they thought they had.
AMBS + MANF
true.. but it is an amendment to existing financing.. so technically its not new
it is accurate to the question that was asked.. AMBS is Transparent
12/30/12
The Company believes the data are positive, even without statistical significance due to small groups of animals in the densitometry and chemistry data, because there are consistent internal results correlating behavior, stereology, densitometry and neurochemistry, most notably at MANF = 10 ug and GDNF = 10 ug. The Company is preparing to initiate IND enabling studies for MANF as a disease-modifying drug candidate for Parkinson's disease.
http://finance.yahoo.com/news/amarantus-bioscience-announces-positive-efficacy-133100600.html
He had not seen the results when that 8k was posted, How can he disagree with something he had not seem? Facts only here please
just be patient.. or not patient depending your position in AMBS
MANF= Mesencephalic astrocyte-derived neurotrophic factor is a secreted protein from the Human Body
AMBS Neuroprotective/Regenerative = MANF
it can repair dying cells , this makes the all the difference in the world comparing it to GDNF
AMBS is WAY undervalued.
Real Story of AMBS
.004
.005
.008
.02
.027
.04
.05
.06
.07
.075
.085
.10
.11
.12
.13
.14
.15
.18
.195
]back down
to .8's
No Float left... Next Big Annoucement
SKY ROCKETS IN FLIGHT.... COVER COVER COVER .20+ 1 day
Every Million will be rewarded 10 to 100 fold..
all Drugs need money to be brought to market..
MANF luckily was so impressive in its latest results that it will probably go from Pre Clininal Straight into Human Trials.... NOW THAT is IMPRESSIVE
do you you know how many Million will be saved thus INCREASING SHARE HOLDER VALUE!!!
Thanks for your AMBS support there is an old saying... Don't fight with your Money..
"The Company maintains that it has not entered into any additional financing transactions since the last 10Q, the Company has not sold any shares and none of the officers or directors have sold any shares. Given the data that is upcoming, the officers and directors are precluded from buying shares in the marketplace at this time until the data is released, as that is material non-public information."
this was straight from the CEO via email to me
No Dilution here.. AMBS = Shareholder Value
show the SEC Filing? you cant ..
TRANSPARENCY = AMBS
MANF is better than GDNF watch VIDEO what GDNF Did for patients before it was pulled because it came from genetically modified cells and the fear of major side effects
Here is the Difference....
MANF is a natural occurring protein in the Human Body...
Watch the VIDEO....
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound.
PR Newswire (http://s.tt/1seN9)
http://www.prnewswire.com/news-releases/amarantus-biosciences-appoints-amgen-co-founder-dr-joseph-rubinfeld-to-advisory-board-177455041.html
This is what sold me... and then he spoke on the companies behalf at BIOTECH SHOWCASE 2013 reiterating the same thing... He is putting his reputation on the line... I AM IN!!!!
MILESTONES
In the last year the AMBS has achieved the following important milestones:
Entered the public markets and significantly expanded our shareholder base;
Confirmed efficacy of our MANF Program in Parkinson's disease;
Received grant funding to initiate our MANF Program in Traumatic Brain Injury.
The most critical milestones for us to achieve in the next 12 months are:
Raising sufficient capital to efficiently fund our therapeutic and diagnostic programs; (Money is coming in)
Advancing our various product development programs to key value inflexion milestones;
Finalizing the business development transactions executed over the past 12 months;
Recruiting seasoned product development expertise in the areas of biopharmaceutical and diagnostic product development; ( DONE )
Listing our common stock on a national stock exchange. ( ON our way)
source:
http://www.amarantus.com/
Amarantus BioSciences secures $10M in equity funding facility
Amarantus BioSciences Inc.closed a $10 million equity funding facility with Centurion Private Equity LLC.
The Sunnyvale-based biotechnology company (OTCBB:AMBS) said it will be able to draw down on the facility over the next 36 months in tranches of up $750,000.
Amarantus BioSciences is developing biologics to treat Parkinson's and other human diseases.
AMBS can still draw on this...
http://www.bizjournals.com/sanjose/news/2011/10/13/amarantus-biosciences-secures-10m.html
LEGIT COMPANIES HAVE MONEY AFFORDED TO THEM WHILE THEY COMPLETE THEIR GROUND BREAKING RESEARCH>>>
BUYER PREPARE for realizing this may the most undervalued company to invest in for 2013 the Inevitable upside is Incredible
Don't be swayed be some with Agendas read the DD up above and see how LEGIT AMBS is and how well run & organized it has displayed.
Just Check the resumes of its board of advisors :
Dr. Joseph Rubinfeld
Corporate Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
Dr. Robert J. Zimmerman
Product Development Advisor
Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities. Previously, he served as Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon. Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.
Dr. Mark Benedyk
Corporate Advisor
Dr. Benedyk, is currently a Managing Partner at Rila Partners LLC, a business and corporate development consultancy he founded earlier in his career. Among other things, in this role, he is a Strategic Advisory Board member to a clinical-stage neuropsychiatry specialty care company, is a Director at the Center for Drug Research and Development Ventures, Inc., and is on the Translational Medicine Advisory Board of the CNS Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI) where his duties included membership on the Board of Directors, a director seat on several TPI portfolio company boards, overseeing the TPI operations team, and reviewing investment opportunities in multiple technologies. Dr. Benedyk also held executive Business Development roles at Ascenta Therapeutics, Optimer Biotechnology, Aurora Biosciences (acquired by Vertex Pharmaceuticals), and Elan Pharmaceuticals. He received his Ph.D. in Developmental Genetics, from The Rockefeller University, his B.S. degrees in Microbiology and Botany from the University of Michigan, B.S., and received financial certifications from Stanford University’s Graduate School of Business, and the University of Virginia Darden School of Business.
Dr. Owen Garrick
Corporate Advisor
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.
Clinton Allen
Corporate Advisor
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.
Mr. Toi Cook
Corporate Advisor
Mr. Cook had an 11 year career in the NFL, playing for the New Orleans Saints, San Francisco 49ers and Carolina Panthers. Mr. Cook had an interception as a defensive back in the 1994Super Bowl championship for the San Francisco 49ers. Since retiring from the NFL, Mr. Cook has worked primarily in Sports and Entertainment. He was Executive Vice President in the Sports Division at the Gersh Agency in Los Angeles from 2004-2006. He is the principle at Toi Cook Management Group, LLC (TCMG), which has consulted for Broadband Sports, A2A Holdings and Dreier Sports. He is currently a plaintiff in a lawsuit of former NFL players against the NFL in relationship to concussions sustained while playing. He served as the Player Representative for the NFLPA for eight years when he was a player in the NFL. He was a football and baseball star at Stanford University, where he graduated in Communications after winning the College World Series in 1987.
Building value from a solid foundation
The data the Company released recently related to our MANF program in Parkinson’s disease is groundbreaking and first of its kind in the Parkinson’s space. Our Chief Scientific Officer, Dr. John Commissiong, presented the data at the OneMedForum 2013 Healthcare Conference, and showed a significant positive impact in every data category, thus supporting advancing MANF in both Investigational New Drug (“IND”)- enabling studies and human clinical studies.
the future has never looked brighter for Amarantus. We have unambiguous data supporting MANF’s further development in our lead Parkinson’s disease indication, we now have rights to seven diagnostic blood tests in significant markets, and our MANF asset continues to make progress in secondary indications. We are looking forward to an exciting 2013 for the Company and its shareholders.
source:
http://www.thechairmansblog.com/gerald-commissiong/2013-01/onwards-and-upwards-building-value-from-a-solid-foundation.html
LEGIT AMBS - has
Basically unlimited earnings potential with MANF. It is found in almost all if not all cell lines in the Human body.
The Indications are almost limitless =
ALL THE CASH TO BE MADE IS INFINITE.
TOP NOTCH COMPANY
I have enough to retire Amount of shares. And i will not be fooled into selling
WWW.BMSN.US website works fine
I believe we start to see a nice ascent Monday, A lot of people will start to realize that AMBS will not need Primate Testing saving a ton of Money and increasing PPS at the same time...
IND'S
ORPHAN DRUG APPS
NUMEROUS MANF INDICATIONS ON THE HORIZON
PPS RISES
NO DILUTION. You FIRST need an 8K-A 1.01 AGREEMENT Saying AMBS secured convertible debentures in principal amount of a total of $XXX,XXX (the "Debentures") from a 3rd party. Then there is a maturing period and AMBS could put in an anti-dilution provision. Then, once the company wants to swap shares for cash an 8k-a 3.02 sale of equity is issued within 2 days of the executed trades.
where is this filing>?
where is the 8k-a 3.02 sale of equity to back up your Guess?
with AMARANTUS there is
NO DILUTION. You FIRST need an 8K-A 1.01 AGREEMENT Saying AMBS secured convertible debentures in principal amount of a total of $XXX,XXX (the "Debentures") from a 3rd party. Then there is a maturing period and AMBS could put in an anti-dilution provision. Then, once the company wants to swap shares for cash an 8k-a 3.02 sale of equity is issued within 2 days of the executed trades.
Firstly, i haven't seen any that will affect PPS. Plus if there was an agreement issued NOW in a 8.01 8k-a that debenture would probably be matured months and months from now.
I hope this enlightens your Guess a bit..
In regards to your comment about AMBS Insider trading regarding SEC Rule 10b5-1. He is acting as a "tipper" for releasing non-public information. Your information and misguided judgement is extremely wrong. Please enlighten the board why there would be a suspension with a fully reporting QB company, who has a very transparent MGMT. Constant 8k-a updates, along with PR. Your logic is mind boggling
-1.4MILLION WAS AMENDED TO ORIGINAL CONVERTIBLE NOTE ON 11/14/12 worth 600k. Lump sum 2.0 million note
"The note is not convertible into common shares for 6 months".
SOURCE: http://ih.advfn.com/p.php?pid=nmona&article=55025946
-From initial 600k convertible note. Why increase financing 230% as an investment? The only reason you invest more because you saw positive results. Such as Dominion Capital says,"Amarantus has made tremendous progress since our initial investment last year. We believe in the assets and the direction of the Company, and are pleased we can contribute to the Company's future growth," added Mikhail Gurevich, Managing Partner, Dominion Capital, LLC.
Well, the time-frame of convertible note happens to be in the same month of Amarantus milestone to up-list.
05/07/2012 @ 5:59AM
"The most critical milestones for us to achieve in the next 12 months are:
Listing our common stock on a national stock exchange"
Source:ih.advfn.com/p.php?pid=nmona&article=52301471
So, the convertible note will be matured 7 days after the up listing takes place.
1. Possible Uplist 5/7/13
2. Maturity date on convertible note: 5/14/13
AMBS gets more people behind them daily, despite having to fight an uphill battle vs some with Agendas
The Financiers say hey here is 250% more money than we already lent you...because we believe in your progress.
This says it all.. slowly but surely despite all the naysayers
AMARANTUS BIOSCIENCE is achieving its goals...
UPLISTING is Inevitable here.
FACE THE FACTS JACK!!!!
AMBS will be ok..its that STRONG
it seems brutal but 1 wrong word and they will delete or remove your post..
i did not see it, but make sure you mention AMBS in all your posts also...
Hang in there.. dont get shaken out of your future gains here with AMBS...
Well this gets stranger each time. Maybe its MM's in training.
Your saying same thing at .0022 BMSN
Keep up nice work. Thanks helping PPS rise
You said that last week. Nice call. Thanks for your efforts in supporting the PPS rise i BMSN
We should frame this post
I am a real samurai. BTW.
AMBS is a long term investment worth being patient for.